Clinical Trial Update: Azithromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas Aeruginosa Ventilator-Associated Pneumonia [Phase 2]

View source ↗

Summary

Phase 2 trial of azithromycin as a quorum-sensing inhibitor to prevent ventilator-associated pneumonia due to Pseudomonas aeruginosa has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Ventilator-associated
• Pseudomonas Aeruginosa Infections

Drugs mentioned

• Azithromycin (azithromycin)

Snippet

Sponsor: Anbics Management-Services Ag | Conditions: Pneumonia, Ventilator-Associated, Pseudomonas Infections | Phase 2 | Status: TERMINATED